131 iodine
Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. Taken orally, sodium iodide I-131 is rapidly absorbed and distributed within the extracellular fluid of the body. The iodide is concentrated in the thyroid via the sodium/iodide symporter, and subsequently oxidized to iodine. The destruction of thyroidal tissue is achieved by the beta emission of sodium iodide I-131. — NCATS
Clinical trial activity
15 trials · 24 clinical orgs · 0 marketing orgs
Earliest trial started Jan 31, 2000 (NCT00115895)
Timeline
Indications
Studied for
- Chalazion · Phase 3
- Colitis, Ulcerative · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- HIV Infections · Phase 1/Phase 2
- Hyperthyroidism · Phase 3
- Radiofrequency Ablation · Phase 3
- Respiratory Tract Infections · Phase 2
- Thyroid Gland · Phase 3
- Thyroid Neoplasms · Phase 3
- Urinary Tract Infections · Phase 2
Mechanism of action
- Unspecified targetRadiodepletion
radiodepletion
Chemistry & pharmacology
SMILES
[131I-]- Mol. weight
- 130.906124168 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS4GC1FOQ22U ↗
Also known as
- 131 iodine
- sun-131
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05142904 | Phase 3 | Nov 17, 2021 | Free University of Amsterdam, Rijnstate Hospital, University of Twente, ZonMw: The Netherlands Organisation for Health Research and Development |
| NCT04871139 | N/A | Apr 8, 2021 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04447183 | Phase 2 | Dec 1, 2020 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT03248440 | Phase 3 | Jul 31, 2017 | Senju Pharmaceuticals |
| NCT03109847 | Phase 2 | Jan 5, 2017 | Thomas Jefferson University |
| NCT02493712 | Phase 2 | Jan 1, 2016 | Holy Stone Healthcare Co., Ltd, inVentiv, Istituto Clinico Humanitas - Rozzano (MI), Italy |
| NCT02338648 | Phase 2 | Oct 1, 2014 | Senju Pharmaceuticals |
| NCT02114619 | N/A | May 1, 2013 | Mashhad University of Medical Sciences |
| NCT01601093 | Phase 2 | Nov 1, 2011 | Nanjing Medical University, Xiangbei Welman Pharmaceutical Co., Ltd |
| NCT01360177 | N/A | Jul 1, 2010 | Stanford University |
| NCT00549523 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2008 | National Center for Complementary and Integrative Health (NCCIH), Office of Dietary Supplements (ODS), University of Missouri |
| NCT01150318 | N/A | Jan 1, 2006 | University of Paris |
| NCT00673010 | Phase 1 | Mar 1, 2005 | Cornell University, Institut Gustave Roussy |
| NCT00196729 | Phase 3 | Dec 1, 2001 | Genzyme |
| NCT00115895 | Phase 3 | Jan 31, 2000 | University of Helsinki |